Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

NCT06267560 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

422

Enrollment

INDUSTRY

Sponsor class

Conditions

Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease

Interventions

DRUG: TQJ230
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals